Accelerate Diagnostics Net Worth
Accelerate Diagnostics Net Worth Breakdown | AXDX |
Accelerate Diagnostics Net Worth Analysis
Accelerate Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Accelerate Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Accelerate Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Accelerate Diagnostics' net worth analysis. One common approach is to calculate Accelerate Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Accelerate Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Accelerate Diagnostics' net worth. This approach calculates the present value of Accelerate Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Accelerate Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Accelerate Diagnostics' net worth. This involves comparing Accelerate Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Accelerate Diagnostics' net worth relative to its peers.
Enterprise Value |
|
To determine if Accelerate Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Accelerate Diagnostics' net worth research are outlined below:
| Accelerate Diagnostics has some characteristics of a very speculative penny stock | |
| Accelerate Diagnostics had very high historical volatility over the last 90 days | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 11.7 M. Net Loss for the year was (50.05 M) with profit before overhead, payroll, taxes, and interest of 2.89 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (24.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: OrthoPediatrics Reports Q4 Loss, Misses Revenue Estimates |
Accelerate Diagnostics Quarterly Good Will |
|
Accelerate Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Accelerate Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Accelerate Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Accelerate Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Accelerate Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Accelerate Diagnostics backward and forwards among themselves. Accelerate Diagnostics' institutional investor refers to the entity that pools money to purchase Accelerate Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ghp Investment Advisors, Inc. | 2024-12-31 | 100.0 |
Follow Accelerate Diagnostics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.55 M.Market Cap |
|
Project Accelerate Diagnostics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.75) | (1.66) | |
| Return On Capital Employed | 13.35 | 14.02 | |
| Return On Assets | (1.75) | (1.66) | |
| Return On Equity | 0.89 | 0.45 |
When accessing Accelerate Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Accelerate Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Accelerate Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Accelerate Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Accelerate Diagnostics. Check Accelerate Diagnostics' Beneish M Score to see the likelihood of Accelerate Diagnostics' management manipulating its earnings.
Evaluate Accelerate Diagnostics' management efficiency
Accelerate Diagnostics has return on total asset (ROA) of (0.6649) % which means that it has lost $0.6649 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 14.02 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.66). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 683.3 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.40) | (2.28) | |
| Tangible Book Value Per Share | (2.40) | (2.28) | |
| Enterprise Value Over EBITDA | (2.16) | (2.27) | |
| Price Book Value Ratio | (0.50) | (0.47) | |
| Enterprise Value Multiple | (2.16) | (2.27) | |
| Price Fair Value | (0.50) | (0.47) | |
| Enterprise Value | 10.1 M | 9.6 M |
Management at Accelerate Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Accelerate Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Accelerate Diagnostics time-series forecasting models is one of many Accelerate Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Accelerate Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Accelerate Diagnostics Earnings per Share Projection vs Actual
Accelerate Diagnostics Corporate Management
| Lawrence Mertz | Chief Officer | Profile | |
| Michael Bridge | Gen VP | Profile | |
| Laura Costa | VP Support | Profile | |
| Rita Boukamel | Senior EMEA | Profile | |
| Maya Gowri | Senior Operations | Profile |
Already Invested in Accelerate Diagnostics?
The danger of trading Accelerate Diagnostics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Accelerate Diagnostics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Accelerate Diagnostics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Accelerate Diagnostics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.